Please login to the form below
Ligelizumab
This page shows the latest Ligelizumab news and features for those working in and with pharma, biotech and healthcare.
Novartis reveals positive efficacy data for Xolair follow-up
Novartis picked up ligelizumab following its acquisition of UK firm Ziarco in 2016. ... If all goes to plan, Novartis is set to file ligelizumab by the end of 2021.
Latest news
-
Novartis highlights emerging assets and late-stage pipeline at R&D day
Ligelizumab (QGE031), a new treatment for chronic spontaneous urticaria, which has phase 3 results and is due to be filed with regulators by the end of 2021.
-
Novartis adds oral eczema drug with Ziarco acquisition
fevipiprant (QAW039) in phase II and ligelizumab (QGE031) for CIU.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Senior Account Manager
-
Competitive
-
Medical Editor
-
Competitive
- PHE study finds people who have had COVID-19 can still transmit the virus
- Sinovac’s COVID-19 vaccine appears safe in older adults
- PHE study finds people who have had COVID-19 can still transmit the virus
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- New study identifies drugs that are safe to use in COVID-19 treatment
- AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine
- Onyx Health Celebrates Its 10th Anniversary with Five New Hires
- Merck’s appeal to restore hepatitis C patent verdict against Gilead fails
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Trial combining British and Russian COVID-19 vaccines could begin in February
- New Oxford research institute established to tackle antimicrobial resistance
- EU proposes vaccine-sharing mechanism with low-income countries
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
- The search for effective drug treatments for COVID-19
- PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
Quick links
Infographics
